Lab trends should be reviewed with a healthcare provider who understands the patient's symptoms, medications, and health history
Key timeline for Eli Lillys orforglipron: The approval of the first oral GLP-1 pill for weight loss expands the treatment landscape for obesity
Wadden | Institutions: Center for Weight and Eating Disorders, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
It is administered subcutaneously and supports flexible dosing frequencies, including micro-dosing, multiple weekly injections, or a once-weekly flex titration schedule
These programs help individuals achieve long-term cholesterol management and weight control, improving both metabolic health and quality of life
Reduction in Loop Diuretic Dose Between baseline and 52 weeks, loop diuretic dose decreased by 17% in the semaglutide group vs